Departments of 1 Physiology and 2 Medicine, University of Toronto, Toronto, Canada M5S 1A8; and 3 Department of Nutrition, University of Montreal, Montreal, Quebec, Canada H3C 3J7
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
To investigate the sites of the free fatty
acid (FFA) effects to increase basal hepatic glucose production and to
impair hepatic insulin action, we performed 2-h and 7-h Intralipid + heparin (IH) and saline infusions in the basal fasting state and
during hyperinsulinemic clamps in overnight-fasted rats. We measured endogenous glucose production (EGP), total glucose output (TGO, the
flux through glucose-6-phosphatase), glucose cycling (GC, index of flux
through glucokinase = TGO EGP), hepatic glucose 6-phosphate (G-6-P) content, and hepatic
glucose-6-phosphatase and glucokinase activities. Plasma FFA levels
were elevated about threefold by IH. In the basal state, IH increased
TGO, in vivo glucose-6-phosphatase activity (TGO/G-6-P), and
EGP (P < 0.001). During the clamp compared with the basal
experiments, 2-h insulin infusion increased GC and in vivo glucokinase
activity (GC/TGO; P < 0.05) and suppressed EGP (P
< 0.05) but failed to significantly affect TGO and in vivo
glucose-6-phosphatase activity. IH decreased the ability of insulin to
increase GC and in vivo glucokinase activity (P < 0.01),
and at 7 h, it also decreased the ability of insulin to suppress
EGP (P < 0.001). G-6-P content was
comparable in all groups. In vivo glucose-6-phosphatase and glucokinase
activities did not correspond to their in vitro activities as
determined in liver tissue, suggesting that stable changes in enzyme
activity were not responsible for the FFA effects. The data suggest
that, in overnight-fasted rats, FFA increased basal EGP and induced hepatic insulin resistance at different sites. 1) FFA
increased basal EGP through an increase in TGO and in vivo
glucose-6-phosphatase activity, presumably due to a stimulatory
allosteric effect of fatty acyl-CoA on glucose-6-phosphatase.
2) FFA induced hepatic insulin resistance (decreased the
ability of insulin to suppress EGP) through an impairment of insulin's
ability to increase GC and in vivo glucokinase activity, presumably due
to an inhibitory allosteric effect of fatty acyl-CoA on glucokinase
and/or an impairment in glucokinase translocation.
glucose-6-phosphatase; glucokinase; total glucose output; glucose cycling
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
THE ASSOCIATION among obesity, insulin resistance, and type 2 diabetes mellitus is well documented (see Refs. 8, 24, 31, and 34 for review). Free fatty acids (FFA) have been implicated as an important causative link among obesity, insulin resistance, and type 2 diabetes mellitus. An elevation of plasma FFA has been shown to impair insulin action and to be a risk factor for the development of type 2 diabetes (40).
In overnight-fasted (liver glycogen-depleted) rats, we have
demonstrated that elevation of FFA, achieved by Intralipid + heparin (IH) infusion, increases endogenous glucose production (EGP) in the basal state and during hyperinsulinemic clamps and, after 7 h,
induces hepatic insulin resistance (28). With the use of the overnight-fasted rat as our experimental model, we wished to study
the effects of FFA on insulin resistance under conditions (stimulated
gluconeogenesis and glycogen depletion) that are relevant to type 2 diabetes. The increase in basal EGP induced by FFA in our model was
probably due to the fact that, after overnight fasting, glycogenolysis
is limited by glycogen depletion (7, 17, 30) and may not
further decrease to provide autoregulation of basal EGP in the presence
of FFA-stimulated gluconeogenesis. We have also suggested that FFA
induces hepatic insulin resistance through hepatic PKC-
translocation (28). However, to this date, the sites of
FFA action on basal EGP and on the suppression of EGP remain unclear.
A regulatory site that is potentially responsible for the FFA-induced
increase in basal EGP and hepatic insulin resistance is the final
common pathway of glucose production and uptake involving glucose-6-phosphatase (G-6-Pase) and glucokinase. G-6-Pase and glucokinase are the enzymes that catalyze the dephosphorylation of
glucose 6-phosphate (G-6-P) (G-6-P glucose)
and the phosphorylation of glucose (glucose
G-6-P),
respectively. Previous studies in rats have shown that a high-fat diet
decreased hepatic glucokinase (39) and decreased
(36) or did not change (39) G-6-Pase activity. However, a high-fat diet decreased the ability of insulin to
suppress G-6-Pase activity (39). Total glucose output
(TGO), which is the flux through G-6-Pase, and glucose cycling (GC), which is an index of flux through glucokinase, were not measured in
these studies.
At the molecular level, IH infusion increased G-6-Pase expression (33), and fatty acyl-CoA esters allosterically stimulated or inhibited G-6-Pase activity in vitro (37). A high-fat diet was found to inhibit glucokinase expression (25), and long-chain acyl-CoA inhibited glucokinase activity through allosteric binding in vitro (49). However, the physiological impact of these effects on EGP, TGO, and GC induced by fatty acids is not known.
In summary, no studies, to our knowledge, have investigated the time course effects of lipid infusion on EGP, TGO, GC, G-6-Pase, and glucokinase activity in the same experiments in vivo. Thus this study was designed to examine whether 1) an elevation of FFA obtained by IH infusion increases basal EGP and induces hepatic insulin resistance (evaluated by comparison of EGP between basal and clamp experiments) through alterations in TGO and/or GC, and 2) these alterations are progressive over time and associated with stable changes in G-6-Pase and glucokinase activity. Stable enzymatic changes, which are determined by the in vitro enzymatic activity assay, refer to the expression levels of the enzyme and any stable enzyme changes (i.e., covalent changes) affecting specific activity. Thus noncovalent allosteric and translocation effects on the enzyme would not be detected by the in vitro assay.
![]() |
RESEARCH DESIGN AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Animal models. Normal female Wistar rats (Charles River, QC, Canada), weighing 250-300 g, were used for experiments. Female Wistar rats were used to allow for future comparison of the effects of FFA with those on female Zucker diabetic fatty, or ZDF, rats, which are a convenient model of high-fat diet-induced diabetes (12). The rats were housed in the University of Toronto's Department of Comparative Medicine. They were exposed to a 12:12-h light-dark cycle and were fed rat chow (Purina 5001, 4.5% fat; Ralston Purina, St. Louis, MO) and water ad libitum. The animal care committee of the University of Toronto approved all procedures.
Surgical procedures. After 3-5 days of adaptation to the facility, rats were anesthetized with ketamine-xylazine-acepromazine (100:0.1:0.5 mg/ml, 1 µl/g body wt), and indwelling catheters were inserted into the right internal jugular vein for infusion and the left carotid artery for sampling. Polyethylene catheters (PE-50; Cay Adams, Boston, MA), each extended with a segment of Silastic tubing (length 3 cm, ID 0.02 in.; Dow Corning, Midland, MI), were used. The venous catheter was extended to the level of the right atrium, and the arterial catheter was advanced to the level of the aortic arch. Both catheters were tunneled subcutaneously and exteriorized. The catheters were filled with a mixture of 60% polyvinylpyrrolidone and heparin (1,000 U/ml) to maintain patency and were closed at the end with a metal pin. The rats were allowed a minimum period of 3-4 days of postsurgery recovery before experiments.
Experimental design. The rats were overnight fasted and randomized to two groups, one of which received IH infusion (20% Intralipid + 20 U/ml heparin, 5.5 µl/min), while the other group was an (equivolume) saline (SAL)-treated control. Both IH- and SAL-treated rats were randomly assigned to different protocols, which varied in the duration of IH/SAL infusion and in the condition of the experimental determinations. The duration of IH or SAL infusion was 2 or 7 h, and experimental determinations were made in the basal fasting state or under conditions of a hyperinsulinemic euglycemic clamp.
For the basal protocols, IH or SAL was infused intravenously for 2 or 7 h through the jugular catheter. A 1:1 mixture of HPLC-purified [2-3H]- and [6-3H]glucose (40 µCi, bolus + 0.8 µCi/min, infusion) was infused through the jugular catheter for 2 h (in the 2-h protocols) or for the last 2 h of the 7-h experiments (in the 7-h protocols) to assess EGP, TGO, and GC. The clamp protocols were similar to basal protocols, but with the addition of an intravenous infusion of insulin resulting in plasma insulin levels in the postprandial range, which was given for 2 h (in the 2-h protocols) or for the last 2 h of the 7-h experiments (in the 7-h protocols). The rate of insulin infusion was 5 mU · kgLaboratory methods. Plasma glucose was measured on a Beckman Glucose Analyzer II (Beckman, Fullerton, CA). Separation of [2-3H]- and [6-3H]glucose was achieved by dimedone precipitation (15). In brief, plasma radioactivity from [2-3H]- and [6-3H]glucose was determined after deproteinization with Ba(OH)2 and ZnSO4, passage through ion exchange columns, and subsequent evaporation. The radioactivity of [6-3H]glucose was determined in an aliquot of the eluate as described by Dunn et al. (14). In all rats studied, the recovery for [6-3H]glucose by the dimedone procedure was quite reproducible and ~95%. The radioactivity of [2-3H]glucose was calculated as the difference between the total radioactivity and that of [6-3H]glucose (corrected for recovery). Aliquots of the infusate tracer mixture and of the radiolabeled glucose infusate were run in parallel with the plasma samples through the dimedone procedure. The intra-assay coefficient of variation was 2.5%, and the interassay coefficient of variation was 6.5%. Insulin and C-peptide levels in plasma were determined by radioimmunoassays with kits specific for rat insulin (but with 100% cross-reactivity with porcine insulin used for infusions) and C-peptide (Linco Research, St. Charles, MO). The interassay coefficients of variation were <9 and 10.5% from insulin and C-peptide, respectively. Plasma FFA levels were measured using a colorimetric kit from Wako Industrials (Osaka, Japan). Plasma triglyceride levels and glycerol levels were also measured using colorimetric kits from Boehringer Mannheim (Mannheim, Germany). Hepatic G-6-P levels were determined by a spectrophotometric method as previously described (37a).
In vitro G-6-Pase activity. The G-6-Pase activity assay allows for determination of the in vitro G-6-Pase activity (expression of G-6-Pase + stable enzyme changes affecting specific activity). Thus noncovalent allosteric effects on G-6-Pase would not be detected by this assay. The liver (~100 mg) was homogenized by hand-held homogenizer (20 times) in 50 mM Tris · HCl at 4°C, pH 7.1. The homogenate was then passed through a 23-gauge needle syringe (5 times) to ensure that the sample was well mixed. G-6-Pase activity (Vmax) was determined in homogenates of liver samples with 50 mM [U-14C]G-6-P at 30°C, as described by Kitcher et al. (26) and van de Werve (50). One unit of enzyme activity is defined as the amount of enzyme protein that is required to synthesize 1 mole of [U-14C]glucose from 1 mole of [U-14C]G-6-P in the conditions of the assay. The Bio-Rad protein assay method was used to measure protein concentration.
In vitro glucokinase activity. The glucokinase activity assay allows for determination of in vitro glucokinase activity (expression level of glucokinase + stable enzyme changes affecting specific activity). Thus noncovalent allosteric effects on glucokinase and the effects on glucokinase translocation would not be detected by this assay. Glucokinase activity was determined by the method described by Bontemps et al. (9) with ~100 mg of liver tissue. The liver was homogenized by hand-held homogenizer (20 times) in buffer A (in mM: 50 triethanolamine, 5 MgCl2, 1 DTT, and 5 EDTA, pH adjusted to 7.5). The homogenate was then passed through a 23-gauge needle syringe (5 times), to ensure that the sample was well mixed, and was subsequently centrifuged at 10,000 g at 4°C. The supernatant was saved for the activity assay. The spectrophotometric assay of glucose-phosphorylating activity was performed at two glucose concentrations: at 100 mM (measures all hexokinases including glucokinase) and at 0.5 mM (measures only the low-Km hexokinases). The difference between the two assays gives glucokinase activity. One unit is the amount of enzyme that catalyzes the formation of 1 µmol of substrate/min, in the conditions of the assay. The Bio-Rad protein assay method was used to measure protein concentration.
Calculations. Glucose turnover [rate of appearance (Ra) of glucose determined with [6-3H]glucose] was calculated using steady-state formulas (48), taking into account the extra tracer infused with the glucose infusate (16). In the basal state, the total glucose Ra corresponds to the EGP. During the clamps, EGP was calculated by subtracting the exogenous glucose infusion rate from the Ra measured with [6-3H]glucose. TGO was determined by subtracting the rates of glucose infusion from the tracer-determining Ra measured with [2-3H]glucose. GC was calculated as the difference between TGO and EGP. In vivo G-6-Pase activity = TGO/hepatic G-6-P content, and under conditions of net glucose production, in vivo glucokinase activity = GC/hepatic glucose derived from G-6-P, i.e., TGO (15, 21, 32, 45). It is worth noting that there are alternative ways of estimating an activity for G-6-Pase and glucokinase that would be pertinent to the exact study conditions by analyzing in vitro measurements of Km by use of the actual G-6-P content measured in the study (3). We used estimates derived from in vivo measurements instead, because we wished to detect substrate and noncovalent allosteric effect on enzyme activity in vivo.
Statistical analysis. Data are presented as means ± SE and refer to the last 30 min of experiments. One-way ANOVA for repeated measures was used to compare differences between treatments (SAL vs. IH). Two-way ANOVA with interaction was used to compare differences between the effects of IH at 2 h and 7 h, with treatment (SAL vs. IH) and duration of infusion (2 h vs. 7 h) as independent variables in both the basal and clamp groups. Two-way ANOVA with interaction was used to compare differences between the effects of IH in basal and clamp groups, with treatment (SAL vs. IH) and experimental conditions (Basal vs. Clamp) as independent variables at both 2 h and 7 h. Statistical calculations were performed using SAS software (Statistical Analysis System, Cary, NC). Significance was accepted at P < 0.05.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
IH elevated plasma FFA levels about threefold in all groups
(P < 0.001; Table 1),
and the levels of FFA were lower during the hyperinsulinemic clamps
than during the basal fasting state, as expected. The triglyceride and
glycerol levels were also elevated by IH and were lower during the
clamps than during the basal experiments (Table 1). Plasma glucose
levels were higher with IH vs. SAL infusion in the basal experiments
but were maintained at ~6.5 mM during the hyperinsulinemic clamps
(Table 1). IH significantly increased plasma C-peptide and
insulin levels in the basal experiments (Table 1), suggesting that FFA
increased endogenous insulin secretion. During the clamps, C-peptide
levels were very low, and IH infusion did not increase C-peptide levels
(Table 1), indicating that insulin secretion was almost completely
suppressed by exogenous hyperinsulinemia with both SAL and IH
infusions. During the clamps, plasma insulin levels were comparable in
all groups (Table 1).
|
Under basal steady-state conditions, IH increased EGP at both 2 h
and 7 h (Fig. 1). There was a
tendency for the effect of IH on EGP to be greater at 7 h vs.
2 h (P = 0.07). During hyperinsulinemic clamps, IH
increased EGP at 2 h (P < 0.001) and 7 h
(P < 0.001; Fig. 1). Two-hour insulin infusion in SAL
experiments suppressed EGP by ~55% (P < 0.05).
Two-hour IH infusion tended to decrease the insulin-induced suppression
of EGP (Basal vs. Clamp), but the effect was not significant
(P = 0.13). Seven-hour IH markedly decreased the
ability of insulin to suppress EGP (P < 0.05; Fig. 1),
indicating hepatic insulin resistance.
|
IH increased basal TGO at both 2 h (P < 0.001)
and 7 h (P < 0.001; Fig.
2). The effect of IH on TGO was greater
after 7-h than after 2-h infusion (P < 0.001; Fig. 2).
During hyperinsulinemic clamps, IH increased TGO at 2 h
(P < 0.001) and 7 h (P < 0.001; Fig. 2). Two-hour insulin infusion tended to suppress TGO, but the
effect was not significant in either SAL or IH experiments (Fig. 2).
|
IH did not affect basal GC after 2-h infusion but tended to increase
basal GC after 7-h infusion (7-h SAL = 1.4 ± 0.7 µmol · kg1 · min
1, 7-h
IH = 6.9 ± 3.7; SAL vs. IH P = 0.10; Fig.
3). During the clamps, 2-h insulin
infusion increased GC (P < 0.05; Fig. 3). IH infusion
decreased insulin's ability to increase GC after 2 h (P
< 0.01) and 7 h (P < 0.01; Fig. 3).
|
The rats infused with glycerol to match the glycerol levels obtained
with IH had EGP, TGO, and GC values similar to those of the SAL-treated
rats (Table 2). As a result, the effects
on EGP, TGO, and GC induced by IH infusion can be attributed mainly to
FFA. The EGP data have already been reported (28).
|
Because EGP = TGO GC, IH increased basal EGP through
increased TGO (flux through G-6-Pase), because IH did not decrease basal GC. During the clamps, insulin decreased EGP mainly through an
increase in GC. IH induced hepatic insulin resistance (decreased the
ability of insulin to suppress EGP) by impairing the ability of insulin
to increase GC. TGO did not play an important role in IH-induced
hepatic insulin resistance because, in the current experimental model,
insulin failed to suppress TGO.
Hepatic G-6-P levels tended to be slightly lower than in
5-h-fasted rats (32) and were comparable in all groups
(Table 3), although 7-h IH infusion
tended to decrease G-6-P content in both the basal
(P = 0.35) and clamp (P = 0.12)
conditions (Table 3). As expected, hepatic G-6-Pase activity was higher
in the current overnight-fasted model than in the 5-h-fasted model
(32). During the basal state, there was a slight decrease
in in vitro G-6-Pase activity after 2-h IH (P = 0.14;
Table 3). This effect became significant after 7-h IH (Table 3). During
the hyperinsulinemic clamps, insulin and IH had no effect on in vitro
G-6-Pase activity (Table 3). Also as expected, hepatic glucokinase
activity was lower in the current overnight-fasted model than in the
5-h-fasted model (32). Although 2-h insulin tended to
increase in vitro glucokinase activity, the effect was not significant
(P = 0.19; Table 3). In vitro glucokinase activity was
not affected by 2-h IH infusion either in basal or clamp experiments
(Table 3). However, in vitro glucokinase activity was suppressed by 7-h
IH infusion in both basal (P < 0.05) and clamp
(P < 0.05) experiments (Table 3). Thus in vitro
activities of G-6-Pase and glucokinase did not correspond to the in
vivo determined flux through the two enzymes. Next, in vivo activities
of the two enzymes were calculated as reported in RESEARCH DESIGN
AND METHODS.
|
Similar to TGO, IH increased basal in vivo G-6-Pase activity
(TGO/G-6-P) at 2 h (P < 0.001) and
7 h (P < 0.001; Table
4). The effect was greater at 7 h
than at 2 h (P < 0.001). Also similar to TGO,
during the hyperinsulinemic clamps, insulin infusion did not have
significant effects on in vivo G-6-Pase activity. Similar to GC, IH did
not affect basal in vivo glucokinase activity (GC/TGO) after 2 h
but had a tendency to increase in vivo glucokinase after 7-h infusion
(P = 0.085; Table 4). Also similar to GC, during the
hyperinsulinemic clamps, insulin infusion increased in vivo glucokinase
activity after 2-h (P < 0.05) and 7-h
(P < 0.05) SAL infusion (Table 4). IH impaired the
ability of insulin to stimulate in vivo glucokinase activity at 2 h (P < 0.01) and 7 h (P < 0.01; Table 4).
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In this study, we have demonstrated that, in overnight-fasted rats, short-term elevation of FFA 1) increases basal EGP through an increase in TGO (flux through G-6-Pase) and 2) induces hepatic insulin resistance through an impairment of insulin stimulation of GC (index of flux through glucokinase). IH elevated basal plasma FFA to levels that were above the physiological range but within the FFA elevation seen in uncontrolled diabetes. The FFA levels in the clamps were lower than the basal FFA levels, a situation consistent with the antilipolytic and FFA reesterification effects of insulin (10). The metabolic conditions of overnight fasting in rats are associated with stimulated gluconeogenesis and glycogen depletion, and thus they are similar to those observed in diabetes.
Basal state. FFA increased TGO, as previously shown in isolated hepatocytes (23), and this effect increased over time. The increase in TGO was responsible for the increase in EGP because FFA did not affect basal GC significantly, as previously shown by Clore et al. in humans (11). TGO is defined as the content of G-6-P times in vivo G-6-Pase activity. Thus the increase of TGO in the basal state could be attributed to an increase in G-6-P content and/or in vivo G-6-Pase activity. The liver G-6-P content, in our experiments, was comparable in all groups, although 7-h IH infusion tended to decrease G-6-P content. This was consistent with previous studies in which palmitate (6) and oleate (23) were found to have no significant effects on G-6-P level in hepatocytes isolated from 24-h-fasted rats. The lack of significant effects of FFA on G-6-P level suggested that the increase in TGO induced by FFA was due largely to increased in vivo G-6-Pase activity. In fact, we have calculated the in vivo G-6-Pase activity, and IH was found to increase in vivo G-6-Pase activity at 2 h and at 7 h, and the effect was progressive over time.
Contrary to the in vivo G-6-Pase activity, the in vitro-determined activity of G-6-Pase activity was not increased by FFA in our model, which underlies the discrepancy between the in vivo and in vitro enzymatic measurements. The G-6-Pase assay that was used in the present study allows for determination of the in vitro G-6-Pase activity (expression of G-6-Pase + stable enzyme changes affecting specific activity) and does not detect allosteric effects on G-6-Pase. This suggests that an increased in vivo G-6-Pase activity through the allosteric stimulation of fatty acyl-CoA on G-6-Pase, as previously shown in vitro (37), could have contributed to the induction of TGO. Massillon et al. (33) showed that IH infusion increased G-6-Pase mRNA and protein levels. The effect of insulin was not addressed in that study (33), because basal insulin levels were maintained with somatostatin and insulin infusion. This stimulation of G-6-Pase expression could have been responsible for the increased in vivo G-6-Pase activity induced by IH in the current study. However, in the present study (with no pancreatic clamp), IH not only failed to increase in vitro G-6-Pase activity (expression of G-6-Pase + stable G-6-Pase changes affecting specific activity) but tended to decrease in vitro G-6-Pase activity at 2 h. Such effect became significant after 7-h IH infusion. In basal experiments with no pancreatic clamp (similar to the current study), Oakes et al. (39) and Garg et al. (19) showed that a high-fat diet did not affect in vitro G-6-Pase activity (19). High-fat diet increased insulin levels in the study of Oakes et al., and the insulin levels were not measured in the study by Garg et al. Thus, in the current study and that by Oakes et al., the slight but prolonged elevation of basal insulin induced by IH and high-fat diet could have prevented detection of increased in vitro G-6-Pase activity, since insulin suppresses G-6-Pase expression (3, 29). Alternatively, or in addition, IH, despite increasing G-6-Pase expression, may decrease in vitro G-6-Pase activity, as suggested by the tendency of IH to decrease G-6-Pase activity at 2 h and by the results of other studies (36, 41). Notably, there is a discrepancy between previous findings of the effect of FFA on in vitro-determined G-6-Pase expression and activity. IH did not affect in vitro glucokinase activity (expression level of glucokinase plus stable enzyme changes affecting specific activity) after 2 h but significantly decreased glucokinase activity after 7 h. The inhibitory effects of IH on in vitro glucokinase activity is in accordance with previous studies in which high-fat diet was found to decrease glucokinase mRNA and activity at weaning in rats (22) and inhibit glucokinase gene expression in lean rats (25). However, the IH-induced decrease in in vitro glucokinase activity did not correspond to a decrease in in vivo glucokinase activity or GC. The fact that GC or in vivo glucokinase activity did not decrease indicates that 1) the rate-limiting step for in vivo glucokinase activity is not glucokinase expression level, and 2) IH increased basal EGP at the site of G-6-Pase and not glucokinase. Because IH increased plasma glucose and insulin levels and basal EGP, it is likely that hepatic insulin resistance may have contributed to the FFA-induced increase in EGP in the basal state, as suggested by our recent findings of FFA-induced PKC-Hyperinsulinemic clamp. Previous studies in dogs and humans have shown that, during hyperinsulinemic euglycemic clamps, there is still net hepatic glucose production under a condition of ~50% (as in the present study), or even greater suppression of EGP (1, 13, 46). Thus under a condition of net hepatic glucose production (basal state and low-dose hyperinsulinemic euglycemic clamp, as in the present study), glucokinase is the rate-limiting factor for GC, as suggested by previous studies (15, 38).
EGP was suppressed through an insulin-induced increase in GC and in vivo glucokinase activity in the SAL infusion groups. Previous studies in humans and dogs (4, 20, 42) have shown that 2-h or 3-h hyperinsulinemic euglycemic clamps did not affect or modestly increased GC when expressed in absolute terms but increased GC when expressed as a percentage of TGO (defined as in vivo glucokinase activity in our study). In 5-h fasted rats, 2-h insulin infusion (~400 pM) did not appear to increase GC above basal levels (43, 44). Furthermore, a 2-h insulin infusion at a high rate (~2,300 pM) even decreased GC (3). The difference in observations may be due to a difference in duration of fasting. In overnight-fasted rats, the in vivo glucokinase activity may be more sensitive to insulin because of liver glycogen depletion. For example, it is well known that, after exercise, the sensitivity of liver glucose uptake to insulin is increased, possibly due to glycogen depletion (27). Thus, in the current study, GC (index of flux through glucokinase) may have become the rate-limiting site for insulin-induced suppression of EGP. On the other hand, in 5-h-fasted rats in which liver glycogen is not depleted, 2-h insulin infusion (~2,300 pM) suppresses EGP through a decrease in TGO (3). The fact that TGO is a rate-limiting site for insulin-induced EGP suppression in 5-h-fasted rats was also supported by a study conducted by Oakes et al. (39), in which 2-h insulin infusion (~550 pM) decreased G-6-Pase activity. In the present study, 2-h insulin infusion achieving insulin levels in the postprandial range did not significantly affect TGO, G-6-P content, in vitro G-6-Pase, and glucokinase activity, although there was a tendency for in vitro glucokinase activity to increase during the hyperinsulinemic clamps. This is in accord with previous studies, in which acute insulin infusion had no effect on in vitro G-6-Pase activity (18, 35, 36, 45) and glucokinase activity (36, 45). However, as discussed above, insulin infusion decreased G-6-Pase activity in a study conducted in 5-h-fasted rats (39). Also, in the high-dose insulin clamp study conducted by Barzilai and Rossetti (3), insulin infusion suppressed EGP through increased glucokinase activity, decreased G-6-Pase activity, and G-6-P content. The discrepancy in observations was probably due to 1) a difference in experimental model (5-h-fasted rats instead of overnight-fasted rats) and/or 2) a difference in insulin levels, as insulin levels were maintained at 2,300 pM in the study of Barzilai and Rossetti compared with ~550 pM in our study. Two-hour and seven-hour FFA elevations increased EGP and TGO during the hyperinsulinemic clamps. FFA tended to decrease the insulin's ability to suppress EGP (comparison between basal and clamp) after 2 h, and the effect became significant after 7-h infusion (hepatic insulin resistance). Insulin infusion did not have any significant effect on TGO in either SAL or IH experiments in our model. Two-hour FFA elevation decreased insulin's ability to stimulate GC (Basal vs. Clamp). Two-hour FFA elevation was also found to decrease the ability of insulin to increase in vivo glucokinase activity (GC/TGO). The in vitro glucokinase activity did not reflect the changes of in vivo glucokinase activity induced by 2-h elevation of FFA, indicating that an impairment in insulin-stimulated glucokinase translocation and/or allosteric inhibitory effect on glucokinase could be responsible for the FFA-induced impairment of insulin's stimulation on GC. This is because translocation and allosteric effects on glucokinase are not detected by in vitro glucokinase activity assays. Indeed, it is tempting to speculate that FFA decreased insulin's stimulation on in vivo glucokinase activity through an impairment of insulin action on glucokinase translocation, because insulin potentiated glucose-induced glucokinase translocation (2), and palmitate partially counteracted glucose-induced glucokinase translocation in hepatocytes (2). The postulated effect of FFA on in vivo glucokinase activity could be direct and/or mediated through impairment of hepatic insulin signaling (possibly through PKC- ![]() |
ACKNOWLEDGEMENTS |
---|
The authors thank Loretta Lam and Guylaine Gévry for excellent technical assistance.
![]() |
FOOTNOTES |
---|
T. K. T. Lam was supported by a Canadian Institute of Health Research Doctoral Award and a Banting and Best Diabetes Centre/Novo Nordisk Studentship. This study was funded by a research grant to A. Giacca from the Canadian Diabetes Association. Part of this work was presented at the 61st Annual Meeting and Scientific Sessions of the American Diabetes Association, June 22-26, 2001, in Philadelphia, PA.
Address for reprint requests and other correspondence: A. Giacca, Univ. of Toronto, Dept. of Physiology, Medical Science Bldg., 1 King's College Circle, Rm. 3363, Toronto, ON M5S 1A8, Canada (E-mail: adria.giacca{at}utoronto.ca).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
10.1152/ajpendo.00332.2002
Received 22 July 2002; accepted in final form 8 October 2002.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Adkins-Marshall, BA,
Myers SR,
Hendrick GK,
Williams PE,
Triebwasser K,
Floyd B,
and
Cherrington AD.
Interaction between insulin and glucose-delivery route in regulation of net hepatic glucose uptake in conscious dogs.
Diabetes
39:
87-95,
1990[Abstract].
2.
Agius, L,
and
Peak M.
Binding and translocation of glucokinase in hepatocytes.
Biochem Soc Trans
25:
145-150,
1997[ISI][Medline].
3.
Barzilai, N,
and
Rossetti L.
Role of glucokinase and glucose-6-phosphatase in the acute and chronic regulation of hepatic glucose fluxes by insulin.
J Biol Chem
268:
25019-25025,
1993
4.
Bell, PM,
Firth RG,
and
Rizza RA.
Assessment of insulin action in insulin-dependent diabetes mellitus using [6(14)C]glucose, [3(3)H]glucose, and [2(3)H]glucose. Differences in the apparent pattern of insulin resistance depending on the isotope used.
J Clin Invest
78:
1479-1486,
1986[ISI][Medline].
6.
Berry, MN,
Phillips JW,
Henly DC,
and
Clark DG.
Effects of fatty acid oxidation on glucose utilization by isolated hepatocytes.
FEBS Lett
319:
26-30,
1993[ISI][Medline].
7.
Beverly, JL,
Yang ZJ,
Koseki M,
and
Meguid MM.
Meal-induced changes in hepatic glycogen of fasted rats.
Physiol Behav
62:
1093-1098,
1997[ISI][Medline].
8.
Boden, G.
Role of fatty acids in the pathogenesis of insulin resistance and NIDDM.
Diabetes
46:
3-10,
1997[Abstract].
9.
Bontemps, F,
Hue L,
and
Hers HG.
Phosphorylation of glucose in isolated rat hepatocytes. Sigmoidal kinetics explained by the activity of glucokinase alone.
Biochem J
174:
603-611,
1978[ISI][Medline].
10.
Campbell, PJ,
Carlson MG,
Hill JO,
and
Nurjhan N.
Regulation of free fatty acid metabolism by insulin in humans: role of lipolysis and reesterification.
Am J Physiol Endocrinol Metab
263:
E1063-E1069,
1992.
11.
Clore, JN,
Glickman PS,
Nestler JE,
and
Blackard WG.
In vivo evidence for hepatic autoregulation during FFA-stimulated gluconeogenesis in normal humans.
Am J Physiol Endocrinol Metab
261:
E425-E429,
1991
12.
Corsetti, JP,
Sparks JD,
Peterson RG,
Smith RL,
and
Sparks CE.
Effect of dietary fat on the development of non-insulin dependent diabetes mellitus in obese Zucker diabetic fatty male and female rats.
Atherosclerosis
148:
231-241,
2000[ISI][Medline].
13.
DeFronzo, RA,
Ferrannini E,
Hendler R,
Felig P,
and
Wahren J.
Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia in man.
Diabetes
32:
35-45,
1983[ISI][Medline].
14.
Dunn, A,
Katz J,
Golden S,
and
Chenoweth M.
Estimation of glucose turnover and recycling in rabbits using various [3H, 14C]glucose labels.
Am J Physiol
230:
1159-1162,
1976
15.
Efendic, S,
Karlander S,
and
Vranic M.
Mild type II diabetes markedly increases glucose cycling in the postabsorptive state and during glucose infusion irrespective of obesity.
J Clin Invest
81:
1953-1961,
1988[ISI][Medline].
16.
Finegood, DT,
Bergman RN,
and
Vranic M.
Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps. Comparison of unlabeled and labeled exogenous glucose infusates.
Diabetes
36:
914-924,
1987[Abstract].
17.
Gannon, MC,
and
Nuttall FQ.
Effect of feeding, fasting, and diabetes on liver glycogen synthase activity, protein, and mRNA in rats.
Diabetologia
40:
758-763,
1997[Medline].
18.
Gardner, LB,
Liu Z,
and
Barrett EJ.
The role of glucose-6-phosphatase in the action of insulin on hepatic glucose production in the rat.
Diabetes
42:
1614-1620,
1993[Abstract].
19.
Garg, ML,
Sabine JR,
and
Snoswell AM.
A comparison of the influence of diets high in saturated versus unsaturated fatty acids on lipid composition and glucose-6-phosphatase activity of rat liver microsomes.
Biochem Int
10:
585-595,
1985[ISI][Medline].
20.
Giacca, A,
Fisher SJ,
Shi ZQ,
Gupta R,
Lickley HL,
and
Vranic M.
Importance of peripheral insulin levels for insulin-induced suppression of glucose production in depancreatized dogs.
J Clin Invest
90:
1769-1777,
1992[ISI][Medline].
21.
Giacca, A,
Groenewoud Y,
Tsui E,
McClean P,
and
Zinman B.
Glucose production, utilization, and cycling in response to moderate exercise in obese subjects with type 2 diabetes and mild hyperglycemia.
Diabetes
47:
1763-1770,
1998[Abstract].
22.
Girard, J,
Perdereau D,
Narkewicz M,
Coupe C,
Ferre P,
Decaux JF,
and
Bossard P.
Hormonal regulation of liver phosphoenolpyruvate carboxykinase and glucokinase gene expression at weaning in the rat.
Biochimie
73:
71-76,
1991[ISI][Medline].
23.
Gustafson, LA,
Neeft M,
Reijngoud DJ,
Kuipers F,
Sauerwein HP,
Romijn JA,
Herling AW,
Burger HJ,
and
Meijer AJ.
Fatty acid and amino acid modulation of glucose cycling in isolated rat hepatocytes.
Biochem J
358:
665-671,
2001[ISI][Medline].
24.
Henry, RR.
Impaired muscle fat metabolism: a cause or effect of visceral obesity?
J Clin Invest
95:
1427-1428,
1995[ISI][Medline].
25.
Jump, DB,
Clarke SD,
Thelen A,
and
Liimatta M.
Coordinate regulation of glycolytic and lipogenic gene expression by polyunsaturated fatty acids.
J Lipid Res
35:
1076-1084,
1994[Abstract].
26.
Kitcher, SA,
Siddle K,
and
Luzio JP.
A method for the determination of glucose-6-phosphatase activity in rat liver with [U-14C]glucose 6-phosphate as substrate.
Anal Biochem
88:
29-36,
1978[ISI][Medline].
27.
Koyama, Y,
Galassetti P,
Coker RH,
Pencek RR,
Lacy DB,
Davis SN,
and
Wasserman DH.
Prior exercise and the response to insulin-induced hypoglycemia in the dog.
Am J Physiol Endocrinol Metab
282:
E1128-E1138,
2002
28.
Lam, TK,
Yoshii H,
Haber CA,
Bogdanovic E,
Lam L,
Fantus IG,
and
Giacca A.
Free fatty acid-induced hepatic insulin resistance: a potential role for protein kinase C-.
Am J Physiol Endocrinol Metab
283:
E682-E691,
2002
29.
Lange, AJ,
Argaud D,
el Maghrabi MR,
Pan W,
Maitra SR,
and
Pilkis SJ.
Isolation of a cDNA for the catalytic subunit of rat liver glucose-6-phosphatase: regulation of gene expression in FAO hepatoma cells by insulin, dexamethasone and cAMP.
Biochem Biophys Res Commun
201:
302-309,
1994[ISI][Medline].
30.
Leander, P,
Mansson S,
and
Pettersson G.
Glycogen content in rat liver. Importance for CT and MR imaging.
Acta Radiol
41:
92-96,
2000[ISI][Medline].
31.
Lewis, GF,
Carpentier A,
Adeli K,
and
Giacca A.
Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes.
Endocr Rev
23:
201-229,
2002
32.
Mason, TM,
Gupta N,
Goh T,
El Bahrani B,
Zannis J,
van de Werve G,
and
Giacca A.
Chronic intraperitoneal insulin delivery, as compared with subcutaneous delivery, improves hepatic glucose metabolism in streptozotocin diabetic rats.
Metabolism
49:
1411-1416,
2000[ISI][Medline].
33.
Massillon, D,
Barzilai N,
Hawkins M,
Prus-Wertheimer D,
and
Rossetti L.
Induction of hepatic glucose-6-phosphatase gene expression by lipid infusion.
Diabetes
46:
153-157,
1997[Abstract].
34.
McGarry, JD.
Glucose-fatty acid interactions in health and disease.
Am J Clin Nutr
67:
500S-504S,
1998[Abstract].
35.
Minassian, C,
Daniele N,
Bordet JC,
Zitoun C,
and
Mithieux G.
Liver glucose-6 phosphatase activity is inhibited by refeeding in rats.
J Nutr
125:
2727-2732,
1995[ISI][Medline].
36.
Minassian, C,
Tarpin S,
and
Mithieux G.
Role of glucose-6 phosphatase, glucokinase, and glucose-6 phosphate in liver insulin resistance and its correction by metformin.
Biochem Pharmacol
55:
1213-1219,
1998[ISI][Medline].
37.
Mithieux, G,
and
Zitoun C.
Mechanisms by which fatty-acyl-CoA esters inhibit or activate glucose-6-phosphatase in intact and detergent-treated rat liver microsomes.
Eur J Biochem
235:
799-803,
1996[Abstract].
37a.
Netheler, HG.
Types of photometer.
In: Methods of Enzymatic Analysis, edited by Bergmeyer HU.. San Diego, CA: Academic, 1974, p. 184-185.
38.
Newsholme, EA,
and
Crabtree B.
Substrate cycles in metabolic regulation and in heat generation.
Biochem Soc Symp
41:
61-109,
1976[Medline].
39.
Oakes, ND,
Cooney GJ,
Camilleri S,
Chisholm DJ,
and
Kraegen EW.
Mechanisms of liver and muscle insulin resistance induced by chronic high-fat feeding.
Diabetes
46:
1768-1774,
1997[Abstract].
40.
Paolisso, G,
Tataranni PA,
Foley JE,
Bogardus C,
Howard BV,
and
Ravussin E.
A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM.
Diabetologia
38:
1213-1217,
1995[ISI][Medline].
41.
Rajas, F,
Gautier A,
Bady I,
Montano S,
and
Mithieux G.
Polyunsaturated fatty acyl coenzyme A suppress the glucose-6-phosphatase promoter activity by modulating the DNA binding of hepatocyte nuclear factor 4 alpha.
J Biol Chem
277:
15736-15744,
2002
42.
Rooney, DP,
Neely RD,
Ennis CN,
Bell NP,
Sheridan B,
Atkinson AB,
Trimble ER,
and
Bell PM.
Insulin action and hepatic glucose cycling in essential hypertension.
Metabolism
41:
317-324,
1992[ISI][Medline].
43.
Rossetti, L,
Giaccari A,
Barzilai N,
Howard K,
Sebel G,
and
Hu M.
Mechanism by which hyperglycemia inhibits hepatic glucose production in conscious rats. Implications for the pathophysiology of fasting hyperglycemia in diabetes.
J Clin Invest
92:
1126-1134,
1993[ISI][Medline].
44.
Rossetti, L,
Massillon D,
Barzilai N,
Vuguin P,
Chen W,
Hawkins M,
Wu J,
and
Wang J.
Short term effects of leptin on hepatic gluconeogenesis and in vivo insulin action.
J Biol Chem
272:
27758-27763,
1997
45.
Shi, ZQ,
Giacca A,
Fisher S,
Vidal H,
van de Werve G,
and
Vranic M.
Importance of substrate changes in the decrease of hepatic glucose cycling during insulin infusion and declining glycemia in the depancreatized dog.
Diabetes
43:
1284-1290,
1994[Abstract].
46.
Sindelar, DK,
Balcom JH,
Chu CA,
Neal DW,
and
Cherrington AD.
A comparison of the effects of selective increases in peripheral or portal insulin on hepatic glucose production in the conscious dog.
Diabetes
45:
1594-1604,
1996[Abstract].
47.
Speth, M,
and
Schulze HU.
Hormone-induced effects on the rat liver microsomal glucose-6-phosphatase system in vitro.
Biochem Biophys Res Commun
99:
134-141,
1981[ISI][Medline].
48.
Stetten, DW,
Welt ID,
Ingle DJ,
and
Morley EH.
Rates of glucose oxidation in normal and diabetic rats.
J Biol Chem
192:
817-830,
1951
49.
Tippett, PS,
and
Neet KE.
Specific inhibition of glucokinase by long chain acyl coenzyme A below the critical micelle concentration.
J Biol Chem
257:
12839-12845,
1982
50.
Van de Werve, G.
Liver glucose-6-phosphatase activity is modulated by physiological intracellular Ca2+ concentrations.
J Biol Chem
264:
6033-6036,
1989
51.
Wiesenthal, SR,
Sandhu H,
McCall RH,
Tchipashvili V,
Yoshii H,
Polonsky K,
Shi ZQ,
Lewis GF,
Mari A,
and
Giacca A.
Free fatty acids impair hepatic insulin extraction in vivo.
Diabetes
48:
766-774,
1999[Abstract].